We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic...
TWYMEEG® sales continue to increase in Japan for the last quarter (July-September) by 5% over the prior quarter and by 23% over the 3rd quarter 2023 Poxel expects TWYMEEG® net sales in Japan in...
Regulatory News: Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). Date Nombre...
Regulatory News : Poxel (Paris:POXEL) : Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic...
Accord avec OrbiMed pour monétiser une partie des redevances issues des ventes de TWYMEEG® à hauteur de 50 millions de dollars sous la forme d’un emprunt obligataire OrbiMed reçoit en...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0185 | -7.55102040816 | 0.245 | 0.248 | 0.218 | 126833 | 0.23262084 | DE |
4 | -0.1045 | -31.5709969789 | 0.331 | 0.3375 | 0.218 | 215775 | 0.27389005 | DE |
12 | -0.3575 | -61.2157534247 | 0.584 | 0.609 | 0.218 | 221802 | 0.38571451 | DE |
26 | -0.4005 | -63.8755980861 | 0.627 | 0.747 | 0.218 | 252768 | 0.51004362 | DE |
52 | -0.1335 | -37.0833333333 | 0.36 | 0.95 | 0.218 | 273257 | 0.55168312 | DE |
156 | -5.2335 | -95.8516483516 | 5.46 | 5.6 | 0.218 | 146899 | 0.91512258 | DE |
260 | -7.2735 | -96.98 | 7.5 | 13.8 | 0.218 | 144456 | 3.38263694 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions